Challenges for receptor theory as a tool for drug and drug receptor classification

Lyotropic ion channel current model compared with ising model

Trans-membrane currents in ligand-gated ion channels are calculated in a non-equilibrium, chemically open whole cell system. The model is lyotropic in the sense that dynamics and parameters such as ligand concentration for half-maximal response (scale of response), and threshold for firing in neurons, are nonlinear functions of the reactant concentrations. The derived total current fits recorded data significantly better than those derived from mass action, Ising, and other equilibrium type models, in which the derived response can be displaced from the assessed response by several orders in the ligand concentration. A comparison of the model obtained with an Ising-like model provides a methodology to obtain the non-equilibrium scaling dependence of Ising-like models on the reactant concentrations.

Qualitative and quantitative assessment of relative agonist efficacy

Historically, the ability of a ligand to bind to its receptor and the ability to subsequently activate that receptor have been described as the properties of affinity and intrinsic efficacy, respectively. These properties were originally believed to be independent of one another; both are possessed by ligands classed as "agonists," and they have served as the quantitative foundation of the drug and receptor classification process. Although affinity has been interpreted readily in physicochemical terms, equivalent molecular models for efficacy remain elusive. In recent times, there has been a significant paradigm shift in our understanding of the interrelationship between affinity and intrinsic efficacy, particularly on theoretical grounds, yet the actual methods available to measure these parameters remain largely operational. Nevertheless, a number of approaches, based on both functional measurements and radioligand binding studies, are available to quantify agonist efficacy on a relative scale and, to date, these remain the most practical. This commentary discusses the most common of these methods, their advantages and limitations, the dependence of the expression of agonism on the chosen assay system, and the impact of recent biochemical and molecular biological advances on the study of efficacy. Additionally, some of the more contemporary theories regarding the molecular nature of efficacy are briefly discussed, as well as the caveats that always must be borne in mind when any determinations of relative agonist efficacy are made.

Schild regression analysis of antidepressant and bicuculline antagonist effects at the GABAA receptor

We showed previously that antidepressants inhibit GABA-stimulated 36Cl- uptake in rat cerebral cortex. In this study Schild analysis was used to determine if antidepressants are competitive antagonists or allosteric modulators at GABAA receptors. GABA concentration-response curves for 36Cl- uptake in rat cerebral cortex were generated in the absence or presence of different concentrations of the following antidepressants: amitriptyline, amoxapine, mianserin, and also the GABAA receptor antagonist, bicuculline. The pA2 values for amitriptyline, amoxapine, mianserin, and bicuculline were 4.2 +/- 0.2, 5.5 +/- 0.3, 4.4 +/- 0.1 and 6.2 +/- 0.6, respectively. The respective Schild slope values were 0.7 +/- 0.1, 0.6 +/- 0.03, 0.7 +/- 0.2 and 1.0 +/- 0.3. All slope values for antidepressants differed from unity. The maximum effect produced by GABA to stimulate chloride influx was decreased by both antidepressants and bicuculline. It is concluded that neither the antidepressants studied nor bicuculline are pure competitive GABA antagonists at the GABAA receptor-chloride-ionophore complex in the rat cerebral cortex.

A simplified empirical approach to evaluate the dissociation constant of a full agonist by the irreversible receptor inactivation method

The estimation of the dissociation constant (Ka) of full agonists represents an essential tool for the classification of drugs and drug receptors, in functional pharmacology. The evaluation of the Ka was a problem until the development of the Furchgott's method (irreversible partial receptor inactivation method), which surely represents the most used analysis for the evaluation of the agonist Ka in experimental protocols on isolated tissues. The Furchgott's method can furnish a reliable estimation of the Ka, but it requires a relatively complicated manipulation of experimental data. In this article, an alternative approach for the evaluation of the Ka is proposed, on the basis of empirical considerations. This method, also based on the partial alkylation of a fraction of receptors, needs only the knowledge of the location parameters of the concentration-response curves and the application of a very simple equation, without any complicated intermediate interpolation of the experimental data.

Efficacy of inverse agonists in cells overexpressing a constitutively active beta2-adrenoceptor and type II adenylyl cyclase

1 Maximal stimulant output from the adenylyl cyclase cascade in neuroblastoma x glioma hybrid, NG108-15, cells is limited by the levels of expression of isoforms of adenylyl cyclase. Stable expression in these cells of a constitutively active mutant (CAM) version of the human beta2-adrenoceptor resulted in higher basal adenylyl cyclase activity than following expression of the human wild type beta2-adrenoceptor. Isoprenaline acted as a full agonist in membranes from both wild type and CAM beta2-adrenoceptor expressing clones. 2 Expression of type II adenylyl cyclase resulted in a substantially elevated capacity of isoprenaline to stimulate [3H]-forskolin binding, whereas in CAM beta2-adrenoceptor expressing cells the basal high affinity [3H]-forskolin binding represented a markedly greater % of the maximal effect which could be produced by addition of isoprenaline, and the EC50 for isoprenaline was some 10 fold lower than in cells expressing the wild type beta2-adrenoceptor. 3 Further transfection of the CAM beta2-adrenoceptor expressing cells with type II adenylyl cyclase greatly increased both absolute basal and agonist-stimulated levels of adenylyl cyclase activity. 4 Betaxolol, ICI 118,551, sotalol and timolol acted as inverse agonists with varying degrees of efficacy, whereas propranolol functioned as a neutral antagonist and alprenolol as a partial agonist. 5 Pretreatment of the CAM beta2-adrenoceptor and type II adenylyl cyclase expressing clones with the irreversible alkylating agent BAAM (1 microM) did not reduce the efficacy of isoprenaline but eliminated efficacy from all the inverse agonist ligands. This effect was dependent upon the concentration of BAAM employed, with half-maximal effects being produced between 10 nM and 100 nM of the alkylating agent, which is similar to the concentrations required to prevent subsequent ligand access to some 50% of the CAM beta2-adrenoceptor population. 6 These data demonstrate that inverse agonist efficacy can be modulated by receptor availability and also indicate why in physiological systems, inverse agonism can be difficult to detect.

Measurement of agonist efficacy using an alpha2A-adrenoceptor-Gi1alpha fusion protein

A fusion protein was constructed between the porcine alpha2A-adrenoceptor and a pertussis toxin-insensitive (Cys351Gly) form of the alpha subunit of the G protein Gi1. Addition of agonist ligands to membranes of COS-7 cells transiently transfected to express this construct, and treated with pertussis toxin prior to cell harvest, resulted in stimulation of both high affinity GTPase activity and enhanced binding of [35S]GTPgammaS. By considering the fusion protein as an agonist-activated enzyme and measuring Vmax of GTP hydrolysis a range of agonist ligands displayed varying efficacy in their capacity to activate the receptor-associated G protein with adrenaline = noradrenaline = alpha-methylnoradrenaline > UK14304 > BHT933 > or = xylazine = clonidine. A similar rank order was observed following independent co-expression of the alpha2A-adrenoceptor and Cys351Gly-Gi1alpha. These data demonstrate the utility and applicability of using a receptor-G protein fusion protein approach, in which the stoichiometry of receptor and G protein is fixed at 1:1, to measure and further understand the nature of agonist efficacy.

Do recent operational studies indicate that a single state model is no longer applicable to G protein-coupled receptors?

Recent evidence suggests that unliganded G protein-coupled receptors exist in at least two states, an inactive conformation and an active conformation possessing affinity for the G protein even in the absence of agonist. The data accumulated so far for wild-type receptors imply that this is true for receptors for several hormones and receptor subtypes, and theoretically for all G protein-coupled receptors. The data now consist of studies implicating not only spontaneous receptor-G protein coupling, but also effector mechanisms and, in the case of transgenic mice over-expressing the human beta 2-adrenoceptor, physiologic responses at the level of the isolated tissue and in vivo. Furthermore, there appear to be ligands (inverse agonists) that can decrease the level of the constitutively active conformation of the receptor, and neutral antagonists can not only block classical agonist responses, but also inhibit the response of inverse agonists.

Extraordinary potency of a novel delta opioid receptor agonist is due in part to increased efficacy

A new cyclic opioid peptide of sequence Tyr-D-Pen-Gly-Phe-Cys-Phe (HBP2) was examined in the mouse isolated vas deferens (MVD) bioassay. Studies with receptor-selective opioid antagonists showed the peptide to be highly selective for delta opioid receptors. HBP2 and the standard delta agonist DPDPE were simultaneously compared using the technique of partial irreversible receptor blockade; data were analyzed using the operational model of pharmacologic agonism. HBP2 was approximately 160 times as potent as DPDPE; estimation of the affinity and efficacy of the two peptides revealed that the potency increase was due to a 5.3-fold increase in efficacy, as well as a 37-fold increase affinity. This contrasts with our previous findings with other cyclic enkephalin analogs, in which increased affinity was achieved without a change in apparent efficacy. Analysis of concentration-response curve shape suggested in addition the possibility of heterogeneity in transduction mechanisms for MVD delta receptors.

New methods for determining dissociation constants of agonist-receptor complexes

Methods are presented which enables the dissociation constant of agonist-receptor complexes (KA) to be estimated without knowledge of the relative intrinsic efficacies. The dissociation constants are estimated from fixed agonist-competitive antagonist concentration combinations which simulate partial agonists. In general, estimating of KA by employing these methods require phi and KB to be known; where phi = [antagonist]/[agonist] and KB is the dissociation constant of the competitive antagonist-receptor complex. Some of these methods require only knowledge of phi, while KB may be unknown. A method is also described to estimate KA without knowing the value of KB and the competitive antagonist concentration. In addition to the estimation of KA values, a new method for estimation of the dissociation constants of competitive antagonist-receptor complexes (KB) is reported. One of the new methods was exemplified practically by using sets of experimental agonist concentration-effect curves determined in the absence and presence of increasing concentrations of competitive antagonists. From this pharmacological data the apparent KA value for carbachol (in muscarinic M3 receptors of the guinea-pig ileum) was determined. This action illustrated that the apparent affinity values (KA) and height of the stimulus curve of an agonist may be determined from published pharmacological data. This procedure affords a possibility to establish whether or not spare receptors are present in a particular system. It was also shown that relative affinity values provide more reliable information than does isolated KA values.

Functional characterization of adenosine A2 receptors in Jurkat cells and PC12 cells using adenosine receptor agonists

The effect of several adenosine analogues on cyclic AMP accumulation was examined in the rat phaeochromocytoma cell PC12 and in the human T-cell leukaemia cell Jurkat, selected as prototypes of cells predominantly expressing adenosine A2A or A2B receptors. Using the reverse transcription-polymerase chain reaction it was, however, demonstrated that the Jurkat cell and the PC12 cell express both A2A and A2B receptor mRNA, albeit in different relative proportions. In PC12 cells the concentration required for half-maximal response (EC50) for the full agonist 5'-N-ethyl-carboxamidoadenosine (NECA) was 30 times lower than in Jurkat cells. There was no significant difference in the pA2 for the antagonist 5-amino-9-chloro-2-(2-furanyl)- 1,2,4-triazolo(1,5-C)quinazolinemonomethanesulphonate (CGS 15943) between the two cell types. In the presence of forskolin (1 microM in PC12 cells; 10 microM in Jurkat cells) the EC50 value for NECA was reduced two-to sixfold. Forskolin also increased the maximal cAMP accumulation twofold in PC12 cells and sevenfold in Jurkat cells. A series of 2-substituted adenosine analogues CV 1808 (2-phenylamino adenosine), CV 1674 [2-(4-methoxyphenyl)adenosine], CGS 21680 ¿2-[p-(2-carbonylethyl)phenylethylamino]-5'-N-ethyl- carboxamido adenosine¿, and four 2-substituted isoguanosines, SHA 40 [2-(2-phenylethoxy)adenosine; PEA], SHA 91 [2-(2-cyclohexylethoxy)adenosine; CEA], SHA 118 ¿2-[2-(p-methylphenyl)ethoxy]adenosine; MPEA¿, and SHA 125 (2-hexyloxyadenosine; HOA), all raised cAMP accumulation in PC12 cells, but had minimal or no effect in Jurkat cells. In the PC12 cells the addition of forskolin (1 microM) reduced the EC50 by a factor of 2(CV 1808) to 12 (SHA 125). In Jurkat cells all the analogues gave a significant, but submaximal, cAMP response in the presence of forskolin (10 microM), but they were essentially inactive in its absence. The results show that a series of 2-substituted adenosine analogues can be used to discriminate between A2A and A2B receptors. The two receptor subtypes appear to coexist, even in clonal cells selected for typical pharmacology. A2 receptor pharmacology can therefore be complex.

Characterization of muscarinic receptors mediating relaxation and contraction in the rat iris dilator muscle

1. The characteristics of muscarinic receptors mediating relaxation and/or contraction in the rat iris dilator muscle were examined. 2. Relaxation was induced in a dilator muscle by application of acetylcholine (ACh) at low doses (3 microM or less) and contraction was induced by high doses. Methacholine and carbachol also showed biphasic effects similar to those of ACh; in contrast, bethanechol, arecoline, pilocarpine and McN-A-343 induced mainly relaxation but no substantial contraction. 3. After parasympathetic denervation by ciliary ganglionectomy, the relaxant response to muscarinic agonists disappeared upon nerve stimulation. Application of McN-A-343 and pilocarpine induced only small contractions in denervated dilator muscles, indicating that these are partial agonists for contraction. 4. pA2 values of pirenzepine, methoctramine, AF-DX 116, himbacine, and 4-DAMP for antagonism to pilocarpine-induced relaxation in normal dilator muscles and those for antagonism to ACh-induced contraction in denervated dilator muscles were determined. The pA2 values for antagonism to relaxation of all these antagonists were most similar to those for M3-type muscarinic receptors. 5. Although pA2 values for contraction of these antagonists, except for methoctramine, were very close to those for relaxation, contraction was not significantly antagonized by methoctramine. Contraction might be mediated by M3-like receptors which have a very low affinity for methoctramine. 6. In conclusion, ACh-induced biphasic responses in rat iris dilator muscles were clearly distinguished from each other by specific muscarinic agonists and parasympathetic denervation, whereas muscarinic receptors could not be subclassified according to the pA2 values of 5 specific antagonists only.

Pertussis toxin-sensitive muscarinic relaxation in the rat iris dilator muscle

1. The effects of pertussis toxin (PTX) on contraction and/or relaxation induced by agonists or transmural nerve stimulation (TNS) were examined in the rat iris dilator and sphincter muscles. 2. TNS in the presence of phentolamine induced an atropine-sensitive biphasic response: initial contraction followed by relaxation in dilator muscles. Exogenously applied acetylcholine (ACh) elicited a large relaxation at low doses (3 microM or less) and a concentration at high doses. 3. Only the ACh-induced relaxation was affected by injection of PTX (10 ng) into the anterior eye chamber. Relaxation was decreased 12 h after injection and had completely disappeared after 24 h. Relaxation recovered in part 3 weeks and almost completely 8 weeks after PTX treatment. A gradual decrease in muscarinic relaxation in a dilator muscle was also observed in vitro after addition of PTX to the bathing solution. 4. The pA2 values of muscarinic blockers, pirenzepine, AF-DX 116, 4-DAMP, and himbacine for competitive antagonism to ACh-induced contraction were 7.14, 6.53, 9.03, and 6.80, respectively, in PTX-pretreated dilator muscles. These values are comparable to those obtained in parasympathectomized dilator muscles and may indicate involvement of M3 or M3-like receptors in muscle contraction. 5. Pretreatment with PTX did not significantly affect contraction induced by noradrenaline or 5-hydroxytryptamine or the relaxation induced by isoprenaline in dilator muscles. 6. In conclusion, among several agonist-induced responses in the rat iris dilator and sphincter muscles, only muscarinic relaxation in dilator muscle occurs via activation of PTX-sensitive GTP binding proteins.

Bioamine receptors: evolutionary and functional variations of a structural leitmotiv

Bioamines act as neurohormonal messengers through their binding to receptors which belong to the largest membrane protein family known so far: the seven spanning membrane receptors. This class of receptors transmits the effect of agonist binding to intracellular effectors by interacting with an intermediary G-protein. The diversity of receptor subtypes inside the protein family, observed in many animal species, is the result of a long evolutionary process. The tendency to protein diversification depends upon gene duplications and upon the continuous accumulation of mutations. The maintenance of vital functions in organisms, however, strictly requires enough structural conservation to ensure the functionality of the corresponding proteins. Both forces cooperate to ensure the adaptation of organisms to a changing environment. We have reviewed here the main conformational and functional constraints exerted on the structure of the bioamine receptors. They are mainly the transmembrane conformation of the receptors, their ability to bind ligands, to interact with G-proteins and to desensitize. The molecular basis of the biochemical and pharmacological differences used to classify the members of the receptor family have also been examined. Interestingly, this classification is very close to that obtained by the molecular phylogeny methods, used to elucidate the evolutionary relationships between bioamine receptors. However, this latter classification allows to accurately distinguish between different receptor subtypes (paralogous genes) and species homologous (orthologous genes). In addition, the calculation of phylogenetical distances reveals two main periods of diversification: the first one occurred before the separation of arthropods from vertebrates, in the Precambrian, and corresponds to the appearance of the main subtypes of the bioamine receptors. The second one, which occurred about 400 million years ago, might accompany the cephalization of the CNS in vertebrates.

The use of the guinea-pig lung parenchyma preparation in studies of the β-adrenoceptor adenylate cyclase system

The binding, adenylate cyclase activation, and functional effect of four beta-adrenoceptor agonists were studied in the guinea-pig lung parenchyma preparation and the results were compared with those obtained earlier in guinea-pig left-heart ventricle (beta 1-adrenoceptors) and soleus muscle (beta 2-adrenoceptors) preparations. The pKi-values of the unselective compounds, isoprenaline and orciprenaline, were in good agreement with those obtained in the heart and soleus muscle. The beta 2-adrenoceptor selective compounds KWD 2026 and terbutaline were bound to two sites, one corresponding to the beta 1-adrenoceptors and the other to the beta 2-adrenoceptors. The pKi-value of isoprenaline was in good agreement with its pKact-value indicating that maximum adenylate cyclase activity is obtained when the occupancy of the receptors is maximal. Further, the relative intrinsic efficacy calculated from the functional effect and receptor occupancy agreed well with the relative maximum adenylate cyclase activation by the agonists which was also found earlier for the guinea-pig heart ventricle and soleus muscle preparations. Relative effects were obtained from both functional experiments and from affinity and adenylate cyclase activating studies. There was good agreement between relative effects obtained in these two ways. It is concluded that the guinea-pig lung parenchyma preparation may be useful for the study of the beta-adrenoceptor adenylate cyclase system.

Influence of lithium pretreatment and of cooling on the responsiveness of the rat isolated jejunum and urinary bladder to muscarinic agonists

1. The aim of the present study was to see whether contractile responses induced by muscarinic agonists in the rat jejunum and urinary bladder were differently affected by procedures that mainly influence the steps following agonist-receptor interaction. Thus, the effects of ex vivo lithium pretreatment (6.8 mmol kg-1 i.p. for 3 days) and in vitro cooling from 37 degrees C to 20 degrees C) on the contractile responses to full and partial agonists, carbachol, oxotremorine, muscarine and pilocarpine were studied. 2. Lithium pretreatment did not affect muscarinic responses on the urinary bladder. It significantly reduced responses to carbachol and oxotremorine but not to muscarine and pilocarpine on the rat jejunum. 3. A decrease of the bath temperature from 37 degrees C to 20 degrees C potentiated responses to carbachol, muscarine and oxotremorine and abolished those to pilocarpine in the urinary bladder. The same lowering of the bath temperature potentiated responses to carbachol, did not affect those to muscarine and to oxotremorine and reduced those to pilocarpine in the jejunum. 4. Together the findings indicate that differences exist in the stimulus-response coupling induced by muscarinic agonists between the two tissues and that, in a given tissue, differences exist among agonists in their ability to activate the agonist-receptor-transducer complex.

Different effects of muscarinic agonists in rat superior cervical ganglion and hippocampal slices

In this study the effects of muscarinic antagonists and agonists on M1 muscarinic receptors in the isolated rat superior cervical ganglion and the rat hippocampal slice were investigated. Oxotremorine and APE but not pilocarpine, McN-A-343 or 4-Cl-McN-A-343 induced small M2 muscarinic receptor-mediated hyperpolarizations in the rat superior cervical ganglion. Nevertheless, for all the agonists investigated the pA2 values of the muscarinic antagonists pirenzepine, AF-DX 116 and p-fluoro-hexahydro-sila-difenidol indicated the presence of only M1 muscarinic receptors in the rat superior cervical ganglion and hippocampal slice. Full agonistic behaviour with respect to depolarization of the rat superior cervical ganglion was observed for pilocarpine, McN-A-343 and 4-Cl-McN-A-343. Oxotremorine and arecaidine propargyl ester were partial agonists in this preparation, with maximal effects of 35 and 46% of the maximum obtained with pilocarpine, respectively. Pilocarpine, oxotremorine and arecaidin propargyl ester displayed full agonistic behaviour on the increase in firing rate of pyramidal cells in rat hippocampal slices. Whereas 4-Cl-McN-A-343 was a partial agonist (maximal effect of 63% of the maximum obtained with pilocarpine), McN-A-343 displayed no agonistic or antagonistic activity in rat hippocampal slices. It remains to be established whether the heterogeneous behaviour of the agonists in both preparations reflects as yet unknown differences in the M1 receptor protein or results from differences in the coupling of receptor to second messenger.

Desensitization and functional antagonism by beta-adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity

1. Apparent affinity constants (KD) for prenalterol, an agonist of low intrinsic efficacy at beta 1-adrenoceptors in rat left atria, have been determined by use of receptor desensitization and functional antagonism induced by isoprenaline and carbachol, respectively. The values obtained have been compared to those values estimated with the irreversible beta-adrenoceptor antagonist, bromoacetylalprenololmenthane (BAAM). 2. The -log KD values for prenalterol estimated by desensitization or irreversible antagonism ranged from 6.8-7.1 and 6.2-7.1, respectively. 3. Carbachol produced functional antagonism of the response to prenalterol even though it was removed before addition of prenalterol. This effect was mediated by M2-muscarinic receptors. Pretreatment of animals with pertussis toxin did not affect the functional antagonism elicited by carbachol. The apparent KD value obtained after pre-exposure to carbachol (6.8) was similar to those estimated by use of either alkylation with BAAM or desensitization with isoprenaline (see above). 4. It is concluded that acute desensitization or functional antagonism of responses to agonists of low intrinsic efficacy provides a means to estimate apparent KD constants. This approach could be useful to characterize receptors for which an irreversible antagonist may not be available.

Biphasic dose-response curves to arecoline in rat atria-mediation by a single promiscuous receptor or two receptor subtypes?

Arecoline produces a biphasic response in rat left atria, i.e., a depression of basal inotropy at low doses and a positive inotropic effect at higher doses. These present studies were designed to determine whether it can be shown that the two separate responses to arecoline are mediated by two distinct cell surface muscarinic receptors. The antagonists scopolamine, 4-DAMP and AF-DX 116 produced apparent simple competitive antagonism of the negative responses to arecoline. Schild analysis was used to measure the equilibrium dissociation constant of the antagonist-receptor complex for antagonism of this response to arecoline by these antagonists. In atria from rats treated with pertussis toxin, the negative inotropy to arecoline was abolished and only the positive inotropic effects were observed. The antagonism of the positive inotropic response to arecoline by these antagonists was studied separately in atria from rats treated with pertussis toxin by the Schild technique. The pKB estimates made from the Schild regressions indicated no evidence to suggest that the two responses to arecoline (negative and positive inotropy) were mediated by two separate receptors in rat left atria. These data are discussed in terms of a single muscarinic receptor in this tissue mediating these two responses by interaction with two G-proteins in the same cell membrane. These data also are discussed in terms of the use of agonist potency ratios for the classification of receptors.

Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta

Competitive antagonists of histamine H1 receptor were investigated for their effects on histamine-induced responses in the rabbit aorta. Antazoline-induced antagonism gave linear Schild plots with slope equal 1, while the other antagonists [+)-brompheniramine, (+/-)-chlorpheniramine, diphenhydramine and mepyramine) produced 'atypical' plots with slopes generally less than unity in the thoracic aorta. Schild plots obtained with these antagonists were evaluated using a two independent component model. The high affinity parameters thus estimated were compatible with those that have been reported for these antagonists. No such heterogeneity was observed in the abdominal aorta when diphenhydramine was investigated with different H1 agonists. The results suggest the presence of at least two components in H1-mediated responses in the thoracic aorta; these components are equally antagonized by antazoline, but differentially antagonized by the other antagonists used.

The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists

Images

Further subclassification of ATP receptors based on agonist studies

Recent studies using agonist analogues of ATP and other nucleotides have generated some surprising observations which may have ramifications for the classification of P2 receptors, particularly for those responses currently attributed to P2Y receptor activation. 2-MethylthioATP (2-MeSATP), the conventional P2Y receptor agonist, does not interact with ATP in the expected fashion in various models of endothelial function, suggesting that it acts by a different mechanism. Furthermore, in certain cell types where responses to ATP are mediated by phospholipase C activation, 2-MeSATP has little or no activity. Interestingly, the pyrimidine uridine triphosphate (UTP) invariably shows similar potency to ATP in systems where 2-MeSATP is inactive. In this article Steve O'Connor and colleagues discuss these data and their significance, and propose that separate receptors may be responsible: one sensitive to 2-MeSATP and the other, a 'nucleotide' receptor, sensitive to UTP.

Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis

Partial receptor inactivation was used as a tool to examine whether differences in receptor reserve exist between the dopamine receptor populations which mediate responses of substantia nigra (A9) and ventral tegmental area (A10) dopamine neurons to dopamine agonist drugs. The irreversible receptor inactivator, N-ethoxycarbonyl-2-ethoxy-1,2- dihydroquinoline (EEDQ), was administered to rats intraperitoneally at a dose of 6 mg/kg (in an ethanol-water vehicle). Approximately 24 h after EEDQ treatments, extracellular, single-unit recording experiments were carried out. In the first series of experiments, dose-response curves were constructed for the inhibition of A9 and A10 dopamine cell firing by intravenous administration of the potent dopamine agonist, R-(-)-N-n-propylnorapomorphine (NPA). For the A9 dopamine cell group, EEDQ pretreatments caused a 3-fold rightward shift in the NPA dose-response curve (ED50S, 0.3 vs 0.8 micrograms/kg for vehicle- and EEDQ-treated rats, respectively), but there was no change in the maximum attainable response (greater than 95% inhibition of cell firing). For A10 neurons, the same EEDQ treatments produced a greater rightward shift in the dose-response curve to NPA (ED50s, 0.6 vs 5.4 micrograms/kg for vehicle- and EEDQ-treated rats), and also depressed the maximum response by about 25% relative to the control (vehicle) curve. The dose-response curves from each region were subjected to Furchgott analysis to determine relative receptor occupancy-response relationships for NPA. For the A9 system, a steep, hyperbolic occupancy-response plot revealed that a 50% inhibitory response required only 4% receptor occupancy, while complete (greater than 95%) inhibition of cell firing required about 30% occupancy. This suggests about a 70% receptor reserve for this agonist in inhibiting A9 dopamine cell firing. The occupancy-response curve for A10 cells was less steep with 50% and maximal (greater than 95%) responses occurring when 11 and 70% of receptors were occupied by the agonist, indicating only about a 30% reserve for A10 cell responses to NPA. While the level of 'spare' receptors differed substantially between the two areas, calculated pseudo-KA values were similar (7.7 micrograms/kg for A9 cells and 5.5 micrograms/kg for A10 cells), suggesting no regional differences in receptor affinity. To explore where the differences in receptor reserve might reside, a second series of studies evaluated the effects of iontophoretically applied dopamine and NPA on both cell groups in vehicle- and EEDQ-treated rats.(ABSTRACT TRUNCATED AT 400 WORDS)

Promiscuous or heterogeneous muscarinic receptors in rat atria? I. Schild analysis with simple competitive antagonists

Carbachol has been shown to produce a biphasic response in rat left atria. At low concentrations, carbachol depresses basal inotropy, while at high doses a positive inotropic effect is observed. The negative inotropic response can be selectively eliminated by pretreatment of rats with pertussis toxin. The aim of these studies was to determine whether or not evidence could be obtained to show that different muscarinic receptors produced these different biochemical responses to the agonist carbachol. Schild analysis was used to measure the equilibrium dissociation constant of the antagonist-receptor complex for antagonism of the negative inotropy to carbachol by atropine, scopolamine 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) and AF-DX 116. The antagonism of the positive inotropic response to carbachol by these antagonists was studied in atria from rats pretreated with pertussis toxin where the negative inotropy was nearly completely abolished. In general, it was found that the antagonists did not produce simple competitive blockade of the positive inotropy but rather a nominal shift to the right of the dose-response curves followed by a depression of maximal responses. However, it was found that when pA2 or pKb values could be calculated, they coincided with those determined for the antagonism of the negative inotropy to carbachol. The conclusion drawn from these experiments was that no evidence was obtained to disprove the null hypothesis that a common receptor, interacting with two G-proteins, mediates these two effects of carbachol in rat left atria. The implications of these data for the classification of drug receptors with agonists is discussed.

Promiscuous or heterogeneous muscarinic receptors in rat atria? II. Antagonism of responses to carbachol by pirenzepine

Carbachol produces both negative and positive inotropy in rat left atria. It is not clear whether these two effects are mediated by two separate cell surface muscarinic receptors or a single receptor interacting with two coupling proteins in the cell membrane. Pirenzepine, known to selectively block some biochemical muscarinic responses, was used in this study to block the biphasic response to carbachol in rat left atria. The negative inotropy to carbachol was blocked by pirenzepine, and Schild analysis indicated a -log dissociation constant (pKb) for the pirenzepine-receptor complex of 6.2. However, the Schild analysis may have been complicated by positive inotropy observed with pirenzepine. This positive inotropic effect was sensitive to blockade by other muscarinic antagonists. In atria from rats pretreated with pertussis toxin, carbachol produced a positive inotropic effect. Schild analysis with pirenzepine for antagonism of this response indicated a -log equilibrium dissociation constant for the pirenzepine-receptor complex of 6.7, significantly different from that for antagonism of negative inotropy. This ostensibly suggested a difference in the receptors mediating these responses. In view of the possible complicating effects of the positive inotropic effects of pirenzepine in this assay, an alternative method for the measurement of pirenzepine affinity was utilized. Resultant analysis was used to measure the pKb for pirenzepine antagonism of negative inotropy to carbachol. This method had the advantage of cancelling the positive inotropy to pirenzepine. Under these circumstances, pirenzepine had a pKb of 6.9, a value not significantly different from for antagonism of the positive inotropy to carbachol. The relevance of these findings is discussed in terms of a single promiscuous muscarinic receptor or heterogeneous receptors in this tissue. These data do not support the hypothesis that two separate receptors mediate these two effects.

Drugs and receptors. An overview of the current state of knowledge

This paper reviews the theoretical concepts and methods utilised with isolated tissues to characterise drugs and drug receptors. Specifically the impact, on the in vitro measurement of agonist affinity and relative efficacy, of the idea that receptors bind to transduction proteins in the lipid bilayer of the cell membrane is discussed. The effects of ternary complex formation of agonist-receptor equilibria raise theoretical objections to the measurement of agonist receptor equilibrium dissociation constants. Possible 'promiscuity' of receptors with respect to the G-proteins with which they can interact makes classification of receptors by agonists suspect. The use of Schild analysis for the measurement of antagonist affinity and subsequent classification of receptors is considered in the light of recent data showing that estimates calculated with this method are heterogeneous. Resultant analysis for the detection of allosteric effects is also discussed. Lastly, the impact of molecular biology on the drug and drug receptor classification process is considered, as well as the effects of pathological processes on drug action at the receptor level.

Pharmacological estimation of agonist affinity: detection of errors that may be caused by the operation of receptor isomerisation or ternary complex mechanisms

1. Recent theoretical studies have questioned the pharmacological estimation of agonist affinity. They showed that when receptor isomerisation or ternary complex mechanisms operate, the receptor inactivation method can substantially overestimate affinity, whereas methods for partial agonist analysis are more accurate. We previously suggested that the operation of such mechanisms and therefore the presence of errors could be detected by analysing the same partial agonist by the receptor inactivation and comparative methods. This paper describes the practical application of this test. 2. The ternary complex mechanism was simulated for a partial agonist under various conditions relating receptor (R) and transducer (T) concentrations, one of which also corresponds to the receptor isomerisation mechanism. The theoretical data so generated were then analysed by the inactivation and comparative methods to quantify the magnitude of error of affinity estimation that could occur. 3. This analysis showed that for a partial agonist with approximately 85% of the activity of a full agonist, the inactivation method could produce an affinity (pKA) estimate up to 0.7 log10 units higher than that produced by the comparative method. This difference would occur when the total receptor concentration ([R0]) is less than or equal to the total transducer concentration ([T0]). It also showed that the overestimation of affinity by the inactivation method was accompanied by drastic overestimation of Em, the maximal effect parameter. 4. The test was then exemplified using the muscarinic receptor system in the guinea-pig isolated left atrial preparation, where there is evidence that a ternary complex mechanism operates. The test agonist was pilocarpine, which produced on average 83% of the activity of the full agonist, carbachol. Pilocarpine was analysed in comparison with carbachol and by receptor inactivation in the same tissue resulting in small and statistically insignificant differences in Em (96.7% and 97.3% respectively) and pKA (5.03 and 4.95 respectively). 5. In conclusion, in this experimental system, there was no evidence for the errors in agonist affinity estimation predicted by theory. Although this conclusion only applies to this system and application of the test to others is necessary to establish the generality of the present results, further examination of the theoretical basis for the predicted errors is required.

Identification of functional oxytocin receptors in lactating rat mammary gland in vitro

The oxytocin (OT) receptor of the lactating rat mammary gland was further characterized by radioligand binding and functional assays in vitro and compared to the uterine OT receptor. In equilibrium saturation binding studies, [3H]OT bound apparently to a single site in mammary tissue with an affinity (Kd = 0.98 nM) similar to that found in the uterus (Kd = 0.68 nM). Using a variety of ligands for OT and arginine vasopressin (AVP) receptors, binding studies indicated that the recognition profile of the mammary [3H]OT binding site closely resembled that found for the uterus but was distinct from the known AVP receptor subtypes. In functional studies, OT and the highly selective OT agonist, [Thr4,Gly7]OT, were potent activators of phosphatidylinositol (PI) turnover in both mammary and uterine slices (EC50 3-5 nM). L-365,209, a novel potent and selective OT antagonist, inhibited OT-stimulated PI turnover in both tissues with similar potencies. These data provide evidence that the high-affinity [3H]OT binding site found in rat mammary tissue during lactation is a functional OT receptor coupled to PI turnover.

An analysis of the beta 2-adrenoceptor selectivity in three series of beta-adrenoceptor agonists

The aim of the study was to analyse the beta 2-adrenoceptor selectivity earlier found in two series of catecholamines and one series of resorcinolamines (Johansson et al. 1986). The affinity of the compounds was assessed in binding studies in preparations from the guinea-pig left heart ventricle (beta 1-adrenoceptors) and the soleus muscle (beta 2-adrenoceptors) using 3H-CGP-12177 as radioligand. Further, the activation of the adenylate cyclase by the compounds was studied in the same preparations. Selectivity quotients were obtained from both functional effects and from affinity and adenylate cyclase activating studies. There was a good correlation between the selectivity quotients obtained in these two ways. Tertiary butyl substitution on the amino nitrogen gave the highest beta 2-adrenoceptor selectivity in both the catechol and resorcinol series. In comparison with their isopropyl substituted analogues the beta 2-adrenoceptor selectivity of these compounds (KWD 2026 and terbutaline) was mainly due to a change in affinity for the beta 1- and beta 2-adrenoceptors and, to a lesser degree, a change in intrinsic efficacy.

Errors in agonist affinity estimation: do they and should they occur in isolated tissue experiments?

Two plausible theories of agonist action - the isomerization and ternary complex mechanisms - predict that agonist affinity measured using the inactivation method may be subject to overestimation. Moreover, the greater the intrinsic efficacy, the greater the predicted error. But are these predictions correct, and are they borne out by experimental data? Paul Leff and colleagues argue that accurate agonist affinity constants can be measured despite these predictions, but that effort must be made to detect any potential errors that might be anticipated from theory.

A set of computer programs to calculate agonist dissociation constants

A series of computer programs have been written to calculate agonist dissociation constants by the method of Parker and Waud (1971). They are faster and less tedious than the manual iterative solutions previously presented, but give comparable results.

Do pharmacological methods for the quantification of agonists work when the ternary complex mechanism operates?

It is well established that many receptors couple to G-proteins in order to subserve their pharmacological or physiological effects. In those systems it is possible that a ternary complex mechanism operates in which initiation of an effect depends on the concentration of agonist-receptor-G-protein complex formed. Such systems may be considered to obey a receptor-transducer model (Black & Leff, 1983, Proc. R. Soc. B220, 141). A theoretical analysis of this model is presented which seeks to determine how the operation of the ternary complex mechanism affects the quantification of agonists by conventional pharmacological methods. Previous analyses have concluded that pharmacological models may or may not accommodate the ternary complex mechanism depending upon the relationship between the relative concentrations of receptor and transducer units, [R0], and [T0] respectively. The present study extends these in two ways. It considers the impact of the ternary complex mechanism on agonist quantification under a more complete range of conditions relating [R0] and [T0], and it does so with regard to the analysis of partial agonists (by the comparative method) as well as of full agonists (by the method of receptor inactivation). The following predictions are made: (i) reliable estimates of affinity and efficacy can be made using the comparative method under the conditions [R0] much greater than [T0] and [R0] much less than [T0] whereas the inactivation method only works under the former condition; (ii) errors occur in the estimation of affinity and efficacy by both methods when [R0] = [T0] although better estimates are produced by the comparative method; (iii) when errors occur in the absolute estimation of affinity and efficacy, the orders of affinity and efficacy determined by the comparative method will generally be correct but this is not the case for the inactivation method; (iv) in general, the comparative method for agonist quantification appears to produce more reliable information for the purposes of receptor classification and medicinal chemistry than does the receptor inactivation method.

Immobilized GABAA receptors and their ligand binding characteristics

ConA-sepharose and polylysine-agarose beads effectively bound detergent-solubilized GABAA receptors from rat cerebrocortical membranes. The immobilized receptors showed a single class of high affinity binding sites specific for flunitrazepam or muscimol and displayed GABA-stimulated flunitrazepam binding. Maximal binding capacities of the ConA-immobilized receptor for the ligands were about three times greater than those of the polylysine-immobilized receptors. The relative affinities for each of the ligands were not affected by the method of receptor immobilization. The dissociation constants for muscimol of these immobilized receptors were somewhat dependent on the solubilizing agents used, but were considerably lower than those measured using extensively dialyzed rat cerebrocortical membranes.

In vivo pertussis toxin treatment attenuates some, but not all, adenosine A1 effects in slices of the rat hippocampus

In order to examine the involvement of G-proteins in mediating the different effects of adenosine A1-receptor stimulation in rat hippocampus we injected pertussis toxin (PTX) intraventricularly close to the hippocampus and examined its effect in slices 48-60 h later. The in vivo PTX treatment caused a partial (50 +/- 5%) inhibition of the [32P]ADP ribosylation produced by PTX added together with [32P]NAD in vitro. Such PTX treatment eliminated the electrophysiologically determined gamma-amino-n-butyric acid (GABA)B receptor response in the hippocampal CA1 region, but GABAA effects were unaffected. The adenosine (50 microM)-mediated hyperpolarization and decrease in input resistance as well as the adenosine-mediated inhibition of low calcium-induced bursting in pyramidal CA1 neurons were virtually abolished. The same was true for the decrease in [3H]cyclic AMP accumulation that is produced by the adenosine analogue R-N6-phenylisopropyl adenosine (R-PIA) in forskolin-treated hippocampal slices. As far as modulation of transmitter release was concerned, the R-PIA (1 microM)-induced inhibition of release of both [3H]noradrenaline (NA) and [3H]acetylcholine (ACh) evoked by field stimulation in hippocampal slices was affected hardly or not at all by pertussis toxin treatment. The inhibitory effect of adenosine on field excitatory postsynaptic potential (EPSP)s evoked in the CA1 region was unaltered by PTX pretreatment. The present results show that in vivo pertussis toxin treatment can inhibit some but not all A1-adenosine-receptor effects. This strongly suggests that closely similar A1 receptors might be coupled to G-proteins that differ in their sensitivity to PTX treatment.